ARQT Arcutis Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.0%
TTM net income YoY167.5%
TTM EPS YoY164.7%
Revenue 3-yr CAGR118.1%
Net income 3-yr CAGR—
Margins
Gross margin91.2%
Operating margin6.9%
Net margin5.9%
FCF margin11.7%
EBITDA margin—
Returns
ROE14.9%
ROA6.7%
ROIC (approx.)10.3%
Asset turnover1.14x
Leverage & solvency
Liabilities / assets53.5%
Debt / equity0.45x
Current ratio2.92x
Interest coverage2.56x
Cash quality & payout
Operating cash flow / net income2.00x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $143.92M | $129.86M | $105.40M | $129.50M | $99.22M | $81.50M | $65.85M | $71.36M |
| Cost of revenue | $12.46M | $10.94M | $9.78M | $11.69M | $8.69M | $7.49M | $8.83M | $6.91M |
| Gross profit | $131.46M | $118.92M | $95.61M | $117.81M | $90.53M | $74.01M | $57.02M | $64.45M |
| R&D expense | $22.42M | $20.36M | $30.63M | $20.45M | $19.60M | $19.45M | $17.54M | $14.48M |
| SG&A expense | $99.60M | $82.14M | $74.08M | $78.98M | $62.40M | $69.17M | $64.00M | $57.61M |
| Operating income | $9.44M | $16.43M | -$9.09M | $18.39M | $8.53M | -$14.61M | -$24.53M | -$7.63M |
| Interest expense | $2.96M | $3.41M | $4.37M | $3.00M | $3.07M | $3.03M | $2.98M | $5.55M |
| Income tax | $195,000 | $136,000 | $93,000 | $470,000 | $80,000 | $342,000 | $279,000 | $323,000 |
| Net income | $8.80M | $15.01M | -$11.29M | $17.39M | $7.41M | -$15.89M | -$25.06M | -$10.79M |
| EBITDA | — | — | — | — | — | — | -$24.38M | -$7.49M |
| EPS (basic) | 0.07 | 0.11 | -0.09 | — | 0.06 | -0.13 | -0.20 | — |
| EPS (diluted) | 0.06 | 0.11 | -0.09 | — | 0.06 | -0.13 | -0.20 | — |
| Weighted avg. shares (diluted) | 136.84M | 135.90M | 129,365 | — | 132.88M | 127.00M | 126,037 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $33.37M | $34.12M | $34.76M | $42.91M | $47.43M | $73.05M | $53.72M | $71.95M |
| Short-term investments | $226.09M | $204.43M | $189.24M | $178.07M | $143.95M | $118.08M | $144.98M | $156.62M |
| Receivables | $171.28M | $155.16M | $144.38M | $146.23M | $115.12M | $106.69M | $85.42M | $73.07M |
| Inventory | $45.67M | $38.88M | $37.39M | $22.63M | $22.42M | $16.32M | $16.61M | $14.53M |
| Current assets | $503.69M | $467.67M | $438.06M | $411.23M | $349.22M | $332.78M | $323.67M | $335.82M |
| PP&E, net | $796,000 | $872,000 | $1.04M | $1.04M | $1.22M | $1.39M | $1.50M | $1.04M |
| Intangibles | $13.12M | $13.69M | $14.25M | $14.81M | $15.38M | $15.94M | $16.50M | $9.48M |
| Total assets | $524.43M | $488.54M | $460.00M | $432.97M | $370.98M | $352.43M | $344.11M | $348.89M |
| Current liabilities | $172.36M | $160.34M | $163.20M | $129.84M | $99.77M | $103.94M | $91.13M | $81.01M |
| Short-term debt | $6.95M | $6.95M | $7.95M | $1.00M | $1.00M | $1.00M | — | $0 |
| Long-term debt | $102.45M | $101.95M | $101.47M | $107.96M | $107.50M | $107.05M | $107.62M | $107.20M |
| Total debt | $109.40M | $108.90M | $109.42M | $108.96M | $108.50M | $108.05M | $107.62M | $107.20M |
| Total liabilities | $280.46M | $267.96M | $270.36M | $243.49M | $212.90M | $213.46M | $201.45M | $191.35M |
| Shareholders' equity | $243.97M | $220.58M | $189.65M | $189.48M | $158.07M | $138.97M | $142.66M | $157.54M |
| Net debt | $76.03M | $74.78M | $74.66M | $66.05M | $61.07M | $35.00M | $53.90M | $35.25M |
| Shares outstanding | 126.02M | 125.59M | 125.04M | 123.33M | 120.29M | 119.80M | 119.14M | 117.85M |
| Cash flow statement | ||||||||
| Operating cash flow | $18.90M | $12.64M | $2.24M | $26.18M | -$1.75M | $324,000 | -$30.38M | -$748,000 |
| Capital expenditure | $97,000 | $158,000 | $0 | $0 | $0 | $78,000 | $608,000 | $0 |
| Free cash flow | $18.80M | $12.48M | $2.24M | $26.18M | -$1.75M | $246,000 | -$30.99M | -$748,000 |
| Investing cash flow | -$22.08M | -$15.22M | -$11.33M | -$34.18M | -$25.25M | $17.42M | $11.75M | $34.88M |
| Financing cash flow | $2.45M | $1.99M | $1.07M | $3.72M | $1.48M | $1.38M | $395,000 | -$97.41M |
| Depreciation & amortization | — | — | — | — | — | — | $153,000 | $145,000 |
| Stock-based compensation | $12.36M | $12.76M | $10.69M | $10.06M | $10.04M | $10.49M | $9.78M | $9.39M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.